Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 17/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 16/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 16/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260638 | 0.91 | NTSR2 (0.46) | NTSR1NTSR2SORT1AGTR1AGTR2 | |
| SCHEMBL5282037 | 0.88 | CMA1 (0.57) | CMA1 | |
| SCHEMBL5282032 | 0.88 | CMA1 (0.57) | CMA1 | |
| SCHEMBL5466307 | 0.84 | OPRK1 (0.41) | NTSR1NTSR2SORT1 | |
| SCHEMBL5275743 | 0.82 | DPP4 (0.51) | NTSR1NTSR2SORT1CMA1 | |
| SCHEMBL5275753 | 0.82 | DPP4 (0.51) | NTSR1NTSR2SORT1CMA1 | |
| SCHEMBL29812856 | 0.79 | AGTR2 (0.46) | NTSR1NTSR2SORT1CMA1AGTR1 | |
| SCHEMBL8366878 | 0.75 | NTSR1 (0.48) | NTSR1NTSR2SORT1AGTR1AGTR2 | |
| SCHEMBL31007073 | 0.75 | CTSD (0.52) | — | |
| SCHEMBL8112052 | 0.75 | CMA1 (0.47) | NTSR1NTSR2SORT1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | NTSR1 2668/4885NTSR2 2591/4885SORT1 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.